Yes, the efficacy and safety of DUPIXENT was evaluated for up to 52 weeks in a multipart, phase 3 clinical trial. Part A and Part B each consisted of a 24-week double-blind treatment period. Subjects who completed Part A or Part B were then eligible to enroll in a 28-week extended active treatment period (Part A-C or Part B-C, respectively)—totaling 52 weeks of treatment.1,3,4

A total of 188 subjects enrolled in the extended active treatment period (77 in Part A-C and 111 in Part B-C). Management of the disease was evaluated through clinical, histologic, and endoscopic endpoints.1,3,4